Drug · DIN 02490005 · Radiopharmaceutical
NETSPOT
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since February 28, 2024; first marketed March 18, 2020.
- Drug Identification Number (DIN)
- 02490005
- Company (DIN owner)
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Schedule
- Schedule c
- Dosage form
- Kit; Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Tumour detection V09I
- Class
- Radiopharmaceutical
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| OXODOTREOTIDE | 40 MCG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 28, 2024: NOC 32789New Drug Submission (NDS) · Administrative - Change in Product Ownership
- July 3, 2019: NOC 22356New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “netspot”. A notice may cover another product or only some lots: read it to see what it covers.
- NETSPOT: Out of SpecificationMarch 24, 2022 · Radiopharmaceuticals · Product quality · Type III